These novel therapies , Tirzepatide , represent a remarkable advancement in managing obesity and conceivably associated disorders. They are categorized as GLP-1 receptor activators , meaning these substances to mimic the endogenous GLP-1 substance , boosting insulin release and suppressing appeti